Atirmociclib in people with normal or reduced liver function
Treatments studied
Part of Digestive system clinical trials.
This study tests how the body handles the medicine Atirmociclib in people with different levels of liver function, from normal to moderate or severe liver disease. It helps doctors understand if the dose needs to be adjusted for people with liver problems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must weigh at least 110 pounds and have a BMI between 17.5 and 40.
- You need to be able to attend all study visits and follow the study plan.
- If your liver function is normal, you must be generally healthy without major medical conditions.
- If you have liver disease, your condition must be stable (no major changes in the last 28 days) and fit into a specific severity category (Child-Pugh A, B, or C).
- You cannot have any condition or past surgery that affects how your body absorbs medications.
- You cannot use certain medications before or during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how the medicine PF-07328948 is processed by people with different levels of liver function. It includes both healthy people and those with stable liver disease (classified as mild, moderate, or severe). The goal is to see if the liver condition affects how the drug works in the body.
This study tests a new medicine called AZD4144 to see how the body handles it in people with different levels of liver function. It may help doctors understand how to dose the medicine for people with liver disease.
This study tests how a new medicine, BI 3000202, is absorbed into the blood. It includes people with different levels of liver function (normal, mild, moderate, or severe) to see if liver problems affect how the medicine works.
This is an early-stage study testing a new medicine called PF-08653944 in healthy adults and in people with varying degrees of liver function problems. The goal is to understand how the medicine works in the body and how liver function affects how the body processes it.
This trial tests two experimental drugs—camizestrant and atirmociclib—for women with advanced ER-positive breast cancer that has worsened after prior treatment. The goal is to see if the combination is safe and tolerable.
This trial tests a drug called palbociclib for people with advanced liver cancer who have already tried at least two other treatments. The goal is to see if palbociclib can help shrink the cancer or slow its growth.
Hear when a new Hepatic Impairment trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.